William Robert Wilson
#139,142
Most Influential Person Now
William Robert Wilson's AcademicInfluence.com Rankings
William Robert Wilsonphilosophy Degrees
Philosophy
#7175
World Rank
#10347
Historical Rank
Logic
#4245
World Rank
#5514
Historical Rank

William Robert Wilsonbiology Degrees
Biology
#9747
World Rank
#12989
Historical Rank
Ecology
#541
World Rank
#594
Historical Rank
Biochemistry
#1501
World Rank
#1629
Historical Rank

Download Badge
Philosophy Biology
William Robert Wilson's Degrees
- Doctorate Medicine Harvard University
Why Is William Robert Wilson Influential?
(Suggest an Edit or Addition)William Robert Wilson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Targeting hypoxia in cancer therapy (2011) (2515)
- Exploiting tumour hypoxia in cancer treatment (2004) (2314)
- Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. (2016) (655)
- Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 (2007) (211)
- A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. (1984) (190)
- Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. (1993) (163)
- The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. (2010) (151)
- Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. (1989) (150)
- Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. (2006) (145)
- Hypoxia-activated prodrugs: paths forward in the era of personalised medicine (2016) (142)
- DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258) (1994) (129)
- Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104 (2011) (120)
- Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. (1986) (114)
- Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors (2010) (111)
- Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. (1998) (107)
- Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. (2010) (105)
- Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. (1998) (104)
- Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. (2003) (103)
- Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (2002) (100)
- A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors (2010) (92)
- Structure−Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine (2003) (92)
- Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia (2000) (92)
- Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. (1981) (89)
- Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. (1984) (89)
- Therapeutic targeting of the hypoxic tumour microenvironment (2021) (86)
- Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. (1995) (84)
- Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. (1994) (82)
- Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. (1986) (82)
- Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. (2007) (81)
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia (2015) (80)
- 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT (2004) (77)
- Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. (1990) (76)
- DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. (2009) (75)
- Selective toxicity of nitracrine to hypoxic mammalian cells. (1984) (75)
- Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. (2002) (75)
- The Design of Selectively‐activated Anti‐cancer Prodrugs for use in Antibody‐directed and Gene‐directed Enzyme‐Prodrug Therapies * (1998) (71)
- Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands (2000) (70)
- Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells. (1984) (69)
- DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. (1990) (68)
- The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia (2011) (67)
- Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. (2008) (66)
- Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. (1994) (65)
- Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. (2006) (64)
- A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients (2011) (64)
- Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. (2007) (64)
- Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia (2012) (63)
- Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards (2007) (63)
- Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A (2009) (62)
- Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. (1994) (61)
- Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. (2003) (61)
- Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. (2008) (61)
- Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. (2015) (59)
- Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. (1992) (59)
- DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine. (2004) (59)
- E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954 (2009) (58)
- Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. (2000) (58)
- Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. (2003) (57)
- PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours (2012) (56)
- Recent developments in the design of bioreductive drugs. (1996) (52)
- SIDE-EFFECTS OF IVERMECTIN IN TREATMENT OF ONCHOCERCIASIS (1989) (51)
- A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. (1999) (51)
- Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores. (2003) (51)
- Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. (1995) (51)
- Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. (2005) (50)
- Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. (1989) (50)
- Pulse Radiolysis Studies on the Fragmentation of Arylmethyl Quaternary Nitrogen Mustards by One-Electron Reduction in Aqueous Solution (1997) (50)
- Design and synthesis of cobalt(III) nitrogen mustard complexes as hypoxia selective cytotoxins. The X-ray crystal structure of bis(3-chloropentane-2,4-dionato)(RS-N,N′-bis(2-chloroethyl)ethylenediamine)cobalt(III) perchlorate, [Co(Clacac)2(bce)]ClO4 (1991) (50)
- Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae (2019) (49)
- The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR (2007) (49)
- Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. (2000) (48)
- DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditions. (2012) (47)
- AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. (2015) (47)
- The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104 (2013) (46)
- Nitro reduction as an electronic switch for bioreductive drug activation. (1997) (45)
- Dual pH-sensitive liposomes with low pH-triggered sheddable PEG for enhanced tumor-targeted drug delivery. (2019) (45)
- Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents. (2009) (45)
- Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins. (2011) (45)
- Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. (1996) (44)
- Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771. (1994) (44)
- Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. (1989) (44)
- Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. (2018) (43)
- Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. (2007) (42)
- Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs) (1993) (42)
- Selective Potentiation of the Hypoxic Cytotoxicity of Tirapazamine by Its 1-N-Oxide Metabolite SR 4317 (2004) (42)
- Targeting hypoxia in the leukemia microenvironment. (2013) (41)
- Reductive metabolism and hypoxia-selective toxicity of nitracrine. (1986) (41)
- Oxygen Dependence of the Metabolic Activation and Cytotoxicity of Tirapazamine: Implications for Extravascular Transport andActivity in Tumors (2004) (41)
- Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. (2007) (41)
- Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides. (2018) (40)
- Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs. (2012) (40)
- Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. (1996) (39)
- Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. (1994) (39)
- Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer (2014) (39)
- Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. (2009) (39)
- Synthesis and Cytotoxicity of 5-Amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2- dihydro-3H-benz[e]indole (Amino-seco-CBI-TMI) and Related 5-Alkylamino Analogues: New DNA Minor Groove Alkylating Agents (1998) (38)
- Bis-tropolonato derivatives of cobalt(III) complexes of bidentate aliphatic nitrogen mustards as potential hypoxia-selective cytotoxins. (1997) (38)
- Prediction of Tumour Tissue Diffusion Coefficients of Hypoxia-Activated Prodrugs from Physicochemical Parameters (2008) (38)
- DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. (1990) (37)
- Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. (2007) (37)
- Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program (2011) (37)
- Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. (1992) (37)
- Optimization of the Auxiliary Ligand Shell of Cobalt(III)(8-hydroxyquinoline) Complexes as Model Hypoxia-Selective Radiation-Activated Prodrugs (2004) (36)
- Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling (2013) (36)
- Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. (2005) (36)
- Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexes. (2004) (36)
- Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. (1996) (34)
- The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. (1990) (34)
- Activity of 4'-(9-acridinylamino)methanesulfon-m-anisidide against Chinese hamster cells in multicellular spheroids. (1981) (33)
- 18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model (2013) (33)
- Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. (2003) (33)
- Hypoxia-selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the "iminoacridan hypothesis". (1990) (33)
- Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs. (2013) (33)
- Evaluation of potential health effects of 10 kHz magnetic fields: a rodent reproductive study. (1998) (33)
- Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators (2009) (32)
- Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures. (1988) (32)
- Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. (1998) (32)
- Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. (2004) (32)
- PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation (2018) (32)
- Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. (1994) (31)
- Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins. (1992) (31)
- Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. (2014) (31)
- A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity (2011) (30)
- A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. (2014) (30)
- Hypoxia-selective radiosensitization of mammalian cells by nitracrine, an electron-affinic DNA intercalator. (1987) (30)
- Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. (1996) (30)
- A NOVEL ENEDIYNE PRODRUG FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) USING E. COLI B NITROREDUCTASE (1995) (30)
- Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. (2007) (29)
- PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma (2011) (29)
- Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. (1999) (29)
- Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. (2000) (29)
- Expression and role in glycolysis of human ADP-dependent glucokinase (2012) (28)
- Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. (2005) (28)
- Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures. (1981) (28)
- Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. (1998) (28)
- NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. (1992) (28)
- Potential of DMXAA combination therapy for solid tumors (2002) (28)
- Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. (2003) (28)
- Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice (2011) (28)
- Radiosensitization of mammalian cells in vitro by nitroacridines. (1990) (28)
- Structure-activity relationships for thiolytic cleavage rates of antitumor drugs in the 4'-(9-acridinylamino)methanesulfonanilide series. (1976) (27)
- FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells. (2013) (27)
- Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma (2015) (27)
- Mechanism of resistance of non-cycling mammalian cells to 4'-[9-acridinylamino]methanesulphon-m-anisidide: role of DNA topoisomerase II in log- and plateau-phase CHO cells. (1988) (27)
- N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization. (1999) (27)
- Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents (2000) (27)
- Cell-cycle-stage specificity of 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and interaction with ionizing radiation in mammalian cell cultures. (1981) (27)
- An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids (2018) (27)
- 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. (1999) (26)
- DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards. (1991) (26)
- Tumour hypoxia: challenges for cancer chemotherapy (1992) (26)
- Characterization of a smart pH‐cleavable PEG polymer towards the development of dual pH‐sensitive liposomes (2018) (25)
- A novel nitro-substituted seco-CI: Application as a reductively activated adept prodrug (1996) (25)
- Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. (1989) (25)
- Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility. (1995) (25)
- Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). (1999) (25)
- Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia (2019) (25)
- The Morphological Effects Of The Anti‐Tumor Agents Flavone Acetic Acid And 5,6‐Dimethyl Xanthenone Acetic Acid On The Colon 38 Mouse Tumor (1994) (25)
- pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells. (2017) (24)
- Pulse radiolysis studies of electron migration in DNA from DNA base-radical anions to nitroacridine intercalators in aqueous solution (1991) (24)
- Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy. (2010) (23)
- Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice. (1983) (23)
- Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. (1998) (22)
- Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans (2010) (22)
- Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. (2016) (21)
- Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study. (2009) (21)
- Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins showing very high in vitro selectivity. (1993) (21)
- An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect12 (2018) (21)
- Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures (2018) (21)
- The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs. (2014) (21)
- Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence* (2013) (20)
- Cellular pharmacology of evofosfamide (TH‐302): A critical re‐evaluation of its bystander effects (2018) (20)
- N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs. (2011) (19)
- Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1. (1996) (19)
- Evaluation of potential health effects of 10 kHz magnetic fields: a short-term mouse toxicology study. (1996) (19)
- Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction. (1994) (19)
- Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy (2011) (18)
- Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin. (1987) (18)
- Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. (1996) (18)
- Ocular involvement in patients with onchocerciasis after repeated treatment with ivermectin. (1990) (18)
- Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine by radiation. (1998) (18)
- N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. (1995) (18)
- SYNTHESIS AND CYTOTOXICITY OF AMINO-SECO-DSA : AN AMINO ANALOGUE OF THE DNA ALKYLATING AGENT DUOCARMYCIN SA (1999) (17)
- Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. (2001) (17)
- Synthesis and hypoxia-selective cytotoxicity of a 2-nitroimidazole mustard. (1998) (16)
- Zinc Finger Nuclease Mediated Knockout of ADP-Dependent Glucokinase in Cancer Cell Lines: Effects on Cell Survival and Mitochondrial Oxidative Metabolism (2013) (16)
- Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice (2017) (16)
- Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs. (1997) (16)
- 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine. (1992) (16)
- Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures. (1987) (15)
- Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. (1990) (15)
- CHAPTER 15 – TUMOR CELL CULTURES IN DRUG DEVELOPMENT (2002) (15)
- Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. (2019) (15)
- Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice (2000) (15)
- Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers. (2014) (15)
- DNA-BINDING NITROHETEROCYCLES AS HYPOXIA-SELECTIVE CYTOTOXINS (1992) (14)
- Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-Oxides. (2016) (14)
- Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models (2019) (14)
- In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. (2004) (14)
- Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid (2004) (14)
- Influence of Mustard Group Structure on Pathways of in Vitro Metabolism of Anticancer N-(2-Hydroxyethyl)-3,5-dinitrobenzamide 2-Mustard Prodrugss⃞ (2008) (14)
- Proliferative assays for the assessment of radiosensitivity of tumor cell lines using 96-well microcultures (1993) (13)
- Hypoxia-selective antitumor agents. 11. Chlorambucil N-oxide: a reappraisal of its synthesis, stability, and selective toxicity for hypoxic cells. (1995) (13)
- In Vitro and In Vivo Models for Evaluation of GDEPT (2004) (13)
- Cytotoxicity and DNA interaction of the enantiomers of 6-amino-3-(chloromethyl)-1-[(5,6,7-trimethoxyindol-2-yl)carbonyl]indo- line (amino-seco-CI-TMI). (1999) (12)
- Differential growth inhibition of cultured mammalian cells: comparison of clinical antitumour agents and amsacrine derivatives. (1984) (12)
- Synthesis and cytotoxicity of amino analogues of the potent DNA alkylating agent seco-CBI-TMI (1997) (12)
- DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A (2017) (12)
- Pathways of Reductive Fragmentation of Heterocyclic Nitroarylmethyl Quaternary Ammonium Prodrugs of Mechlorethamine (2002) (12)
- Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors (2019) (11)
- Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? (1994) (11)
- Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921. (1986) (11)
- Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy. (2010) (10)
- The fate of N1'-methanesulphonyl-N4'-(9-acridinyl)-3'-methoxy-2',5'-cyclohexadiene- 1',4'-diimine (m-AQDI), the primary oxidative metabolite of amsacrine, in transformed Chinese hamster fibroblasts. (1990) (10)
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: HYPOXIA‐ACTIVATED PRODRUGS AS ANTITUMOUR AGENTS: STRATEGIES FOR MAXIMIZING TUMOUR CELL KILLING (1995) (9)
- Nitroacridines with selective toxicity towards hypoxic mammalian cells: Synthesis and stability of tritiated derivatives (1985) (9)
- Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide (2019) (9)
- The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins. (2011) (9)
- Pulse radiolysis studies on the hypoxia-selective toxicity of a colbalt-mustard complex. (1996) (9)
- Nitrogen and sulfur analogues of the secoCI alkylating agent: Synthesis and cytotoxicity (1996) (9)
- Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity. (1999) (9)
- The design of cobalt(III) complexes of phenazine-1-carboxamides as prointercalators and potential hypoxia-selective cytotoxins. (1999) (9)
- Effect of reduction potential on the rate of reduction of nitroacridines by xanthine oxidase and by dihydro-flavin mononucleotide (1991) (9)
- Effects of amsacrine and other DNA-intercalating drugs on nuclear and nucleolar structure in cultured V79 Chinese hamster cells and PtK2 rat kangaroo cells. (1985) (8)
- Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine. (1987) (8)
- Abstract B76: Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia‐activated irreversible pan‐HER inhibitor (2009) (8)
- Nitroacridines and Nitroquinolines as DNA-Affinic Hypoxia-Selective Cytotoxins (1990) (8)
- Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins. (1996) (8)
- Synthesis and Cytotoxicity of Amino‐seco‐DSA: An Amino Analogue of the DNA Alkylating Agent Duocarmycin SA. (1999) (7)
- Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution. (2014) (7)
- Efficient redox cycling of nitroquinoline bioreductive drugs due to aerobic nitroreduction in Chinese hamster cells. (1995) (6)
- Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5. (2000) (6)
- Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966. (2011) (6)
- Discovery of the hypoxia-activated prodrug SN30000 (2017) (6)
- The reaction between nitracrine and glutathione: implications for hypoxic cell radiosensitization and cytotoxicity. (1989) (6)
- Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis (1990) (5)
- 496 Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins (2004) (5)
- Correlation of the radiosensitization potency afforded by nitroacridine intercalators with their electron scavenging efficiency in DNA. (1992) (5)
- Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000 (2019) (5)
- Nitro analogues of chlorambucil as potential hypoxia-selective anti-tumour drugs. (1990) (5)
- Final results of a phase Ib trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors. (2010) (5)
- In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma. (1986) (5)
- Crystallographic and oxygen-17 NMR studies of nitro group torsion angles in a series of 4-alkylaminonitroquinolines designed as hypoxia-selective cytotoxins (1992) (5)
- Drug‐DNA adducts as biomarkers for metabolic activation of the nitro‐aromatic nitrogen mustard prodrug PR‐104A (2018) (5)
- Metabolic and radiolytic reduction of 4-alkylamino-5-nitroquinoline bioreductive drugs. Relationship to hypoxia-selective cytotoxicity. (1994) (5)
- Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia. (2013) (4)
- Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia. (2009) (4)
- A Novel Nitro‐Substituted seco‐CI: Application as a Reductively Activated Adept Prodrug. (1997) (4)
- DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol. [Erratum to document cited in CA121:300815] (1995) (4)
- Nitrogen and Sulfur Analogues of the seco-CI Alkylating Agent: Synthesis and Cytotoxicity. (1997) (4)
- Ocular and systemic side effects following ivermectin treatment in onchocerciasis patients from Sierra Leone. (1990) (4)
- Studies on the mode of action of the antitumour acridine 4'-(9-acridinylamino)methanesulphon-m-anisidide (m-AMSA) (1978) (4)
- Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity (2020) (4)
- A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors (2007) (3)
- Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents. (2000) (3)
- Abstract 1660: The antitumor action of ASA404 (vadimezan; DMXAA); potential involvement of vascular endothelial growth factor (VEGF) (2010) (3)
- Abstract C46: Design and identification of the novel hypoxia‐activated irreversible pan‐HER inhibitor SN29966 (2009) (3)
- DNA-Directed Alkylating Agents. Part 4. 4-Anilinoquinoline-Based Minor Groove Directed Aniline Mustards. (1991) (3)
- Weight loss effects of quaternary salts of 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles; structure-activity relationships. (2012) (3)
- Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors (2019) (3)
- Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648. (2021) (3)
- The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids. (1992) (3)
- 473 POSTER The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase) (2008) (3)
- Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection (2011) (3)
- Sensitive liquid chromatographic assay for the basic DNA intercalator (N,N-dimethylaminoethyl)-9-amino-5-methylacridine-4-carboxamide and its nitroarylmethyl quaternary prodrugs in biological samples. (2001) (2)
- An indoline-derived compound that markedly reduces mouse body weight (2013) (2)
- N‐Substituted 2‐(2,6‐Dinitrophenylamino)propanamides: Novel Prodrugs That Release a Primary Amine via Nitroreduction and Intramolecular Cyclization. (1999) (2)
- Inhibition of tumor blood flow. (2000) (2)
- Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug (2021) (2)
- Calcium Enabled Remote Loading of a Weak Acid Into pH-sensitive Liposomes and Augmented Cytosolic Delivery to Cancer Cells via the Proton Sponge Effect (2022) (2)
- Targeting Tumor Hypoxia with Prodrugs: Challenges and Opportunities (2008) (2)
- Abstract 2440: Potentiation of the action of chemotherapeutic drugs by the hypoxia-activated prodrug SN30000 in multicellular tumor spheroids (2018) (2)
- Nitrobenzyl Carbamate Prodrugs of Enediynes for Nitroreductase Gene‐Directed Enzyme Prodrug Therapy (GDEPT). (2000) (2)
- EF5 as a predictive biomarker for activation of the new hypoxia-targeting prodrug SN30000. (2011) (2)
- Molecular determinants of T-cell acute lymphoblastic leukaemia sensitivity to the pre-prodrug PR-104 (2012) (2)
- Prodrug Strategies for Targeting Tumour Hypoxia (2014) (2)
- Pulse radiolysis studies on the oxidation of OH˙ radical-damaged DNA by nitroquinolines in aqueous solution (1995) (2)
- Abstract 41: Role of the novel glucose-phosphorylating enzyme ADP-dependent glucokinase in human cancer cell lines featuring knockouts generated by zinc finger nucleases (2010) (1)
- Random clonal expansion as a limiting factor in transplantable in vivo CRISPR/Cas9 screens (2021) (1)
- Effect of cell type and drug lipophilicity on the extravascular transport of small molecule anticancer drugs: tirapazamine analogs (2005) (1)
- PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours (2012) (1)
- A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors (2008) (1)
- Synthesis and Cytotoxicity of 5-Amino-1-(chloromethyl)-3- [(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-diyhdro-3H-benz[e]indole (Amino-seco-CBI-TMI) and Related 5-Alkylamino Analogues: New DNA Minor Groove Alkylating Agents. (1999) (1)
- Development of capability for genome-scale CRISPR-Cas9 knockout screens in New Zealand (2018) (1)
- Abstract 2111: Identification of reductases capable of metabolic activation of hypoxia targeting prodrug SN30000 and hypoxia marker EF5. (2013) (1)
- Abstract 5306: 18F-EF5 microPET imaging of treatment response from a novel, hypoxia-selective cytotoxin SN30000 in a human lung cancer xenograft model (2011) (1)
- 258 POSTER Tricyclic triazin 1,4-dioxides: a new class of hypoxia-selective cytotoxins with improved extravascular transport compared to tirapazamine (2006) (1)
- Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104 (2010) (1)
- Studies of Naphthalene Diimides as DNA-binding Agents (1997) (1)
- Abstract 453: Identification of human oxidoreductases involved in the hypoxia-dependent activation of bioreductive prodrugs (2010) (1)
- 412P Effects of statins on melanoma (2016) (1)
- Abstract 4513: Investigation of bystander effects of hypoxia activated prodrugs using three dimensional cell cultures (2017) (1)
- Drugging Tumour Hypoxia: Resolving the Complexity Using Functional Genetic Screens (2015) (0)
- Agent-based models for prediction of tumor spheroid response to radiation and the hypoxia-activated prodrug SN30000 (Abstract #4523) (2017) (0)
- Compositions of DMXAA and other anticancer agents (2002) (0)
- Abstract SY34-01: New prodrugs for targeting tumor hypoxia (2010) (0)
- Hypoxia-activated prodrugs of DNA-dependent protein kinase as radiosensitisers (2020) (0)
- Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit (2021) (0)
- Combinations of DMXAA and other anticancer agents. (2002) (0)
- 259 POSTER Substituted nitro(chloromethyl)benzindolines (nitroCBls): a new class of hypoxia selective cytotoxins with in vivo activity (2006) (0)
- Abstract C21: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumor patients. (2011) (0)
- Effect of POR knockout on hypoxic prodrug activation (2013) (0)
- 1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam (2018) (0)
- Polymeric Micellar Carriers for a Hydrophobic Anti-cancer Drug (2013) (0)
- Final results of a phase I trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, given weekly to solid tumor patients. (2010) (0)
- 260 POSTER SN 30000: a tricyclic triazine 1,4-dioxide hypoxia-selective bioreductive drug with superior in vivo activity to tirapazamine (2006) (0)
- 492 Novel hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with improved extravascular transport: analogues of Tirapazamine with in vivo activity (2004) (0)
- Crystallographic and 17O NMR Studies of Nitro Group Torsion Angles in a Series of 4-Alkylaminonitroquinolines Designed as Hypoxia-Selective Cytotoxins. (1992) (0)
- Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit (2021) (0)
- Synthesis and Cytotoxicity of Amino Analogues of the Potent DNA Alkylating Agent seco‐CBI‐TMI. (1997) (0)
- Remote Loading of a Novel Acidic Hypoxia-Activated Prodrug into Liposomes with High Entrapment Efficiency and Drug Loading Ming ( (2014) (0)
- Indane derivatives for antipsychotic agents (1997) (0)
- Small Molecule Therapeutics Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer (2014) (0)
- Identification of a lead hypoxia-activated irreversible pan-HER inhibitor SN32807 (PR509) by pharmacokinetic and anti-tumor efficacy screening in an erlotinib-resistant xenograft model (2011) (0)
- Clinical Cancer esearch cer Therapy : Preclinical rmacokinetic / Pharmacodynamic Modeling Identifies 0000 and SN 29751 as Tirapazamine Analogues with roved Tissue Penetration and Hypoxic R l Killing in Tumors (2010) (0)
- PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation (2018) (0)
- 474 POSTER Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models (2008) (0)
- S23 03 WA – DNA-BINDING NITROHETEROCYCLES AS HYPOXIA-SELECTIVE CYTOTOXINS (1991) (0)
- Nitroanilinderivater and their use as antitumor agents (1992) (0)
- 204 High-throughput functional screening identifies the flavoreductase POR as a principal determinant of sensitivity to the hypoxia-targeting prodrug SN30000 (2014) (0)
- 263 POSTER Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial (2006) (0)
- Abstract PO-018: Hypoxia activated prodrugs of DNA-dependent protein kinase inhibitors as radiosensitisers of head and neck squamous cell carcinomas (2021) (0)
- DMD # 30973-1-Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice , Rats , Dogs and Humans (2009) (0)
- Hypoxia-Selective Antitumor Agents. Part 14. Synthesis and Hypoxic Cell Cytotoxicity of Regioisomers of the Hypoxia-Selective Cytotoxin 5- (N,N-Bis(2-chloroethyl)amino)-2,4-dinitrobenzamide. (2010) (0)
- 983 The Role of Bystander Effects in the Anti-tumour Activity of the Hypoxia-activated Prodrug PR-104a (2012) (0)
- Hypoxia-Selective Antitumor Agents. Part 7. Metal Complexes of Aliphatic Mustards as a New Class of Hypoxia-Selective Cytotoxins. Synthesis and Evaluation of Cobalt(III) Complexes of Bidentate Mustards. (1993) (0)
- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs (2015) (0)
- Cobalt and chromium complexes as radiation-activated cytotoxins (1997) (0)
- Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma (2023) (0)
- Abstract 2745: AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104. (2013) (0)
- 1015 POSTER Evaluation of the Role of the Novel Glucose-phosphorylating Enzyme ADP-dependent Glucokinase in Human Tumour Cell Lines Using Zinc Finger Nuclease Gene Knockouts (2011) (0)
- 305 POSTER Structure–activity relationships for lipophilic dinitrobenzamide mustards as prodrugs for Escherichia coli NfsB nitroreductase (2008) (0)
- Investigation of bystander effects of hypoxia activated prodrugs using three dimensional cell cultures (Abstract #4513) (2017) (0)
- 247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria (2018) (0)
- Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia (2012) (0)
- LYMPHOID NEOPLASIA AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia (2015) (0)
- Quantitative structure-activity relationships for the cytotoxicity of substituted aniline mustards in tissue culture (1989) (0)
- Abstract LB-297: Characterization of novel hypoxia-activated prodrugs of irreversible pan-HER inhibitors (2010) (0)
- the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model (2013) (0)
- Hypoxia‐Selective Antitumor Agents. Part 8. Bis(nitroimidazolyl) alkanecarboxamides: A New Class of Hypoxia‐Selective Cytotoxins and Hypoxic Cell Radiosensitisers. (1994) (0)
- Abstract 4523: Agent-based models for prediction of tumor spheroid response to radiation and the hypoxia-activated prodrug SN30000 (2017) (0)
- Functional genomics screens to identify genes involved in tolerance of tumour microenvironment stress (2020) (0)
- Erratum to: Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice (2011) (0)
- Plateau-Phase Chinese Hamster Fibroblast Cell Cultures Uptake , Metabolism , and DNA Breakage in Log-and-anisidide : Comparison of m-( 9-Acridinylamino ) methanesulfon-′ Mechanism of Resistance of Noncycling Mammalian Cells to 4 Updated (2006) (0)
- 498 Selective potentiation of the hypoxic cytotoxicity of the bioreductive drug tirapazamine (2004) (0)
- 1,2,4-tri-cyclic triazinoxide and compositions thereof for the therapeutic application in cancer treatment (2006) (0)
- Abstract 5853: Identification ofTSC1andTSC2as potential determinants of sensitivity to trastuzumab emtansine (2020) (0)
- 203 Hypoxic Leukemic Microenvironment and its Targeting by the Hypoxia-Activated Prodrug PR-104 (2011) (0)
- Pharmacodynamic biomarkers for the hypoxia-activated nitrogen mustard PR-104; DNA interstrand crosslinks and γH2AX in human tumor cell lines and xenografts (2007) (0)
- 300 POSTER Oncolytic adenovirus ONYX-411NTR enhances the antitumour efficacy of the bioreductive alkylator prodrug PR-104 (2008) (0)
- Abstract 2272: Comparison of bioreductive metabolism of tirapazamine, its second generation analogue SN 30000 and hypoxia imaging agent EF5 in human tumor cell lines (2010) (0)
- Abstract 169: Preclinical efficacy and sensitivity determinants of evofosfamide in molecularly defined models of head and neck squamous cell carcinoma (2017) (0)
- P32 21 TP – PULSE RADIOLYSIS STUDIES OF INTRAMOLECULAR ELECTRON TRANSFER IN DNA TO ELECTRON-AFFINIC INTERCALATORS (1991) (0)
- Expression and role in glycolysis of human ADP-dependent glucokinase (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William Robert Wilson?
William Robert Wilson is affiliated with the following schools: